This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Medical Xpress - Cardiology
JANUARY 10, 2025
Stanford University School of Medicineled researchers have found that intensive blood pressure (BP) control produces cardiovascular benefits and increases the risk of adverse events in people with chronic kidney disease (CKD).
128 
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
HCPLive
MARCH 26, 2024
A study in China identified a negative and non-linear relationship between hemoglobin levels and a renal composite end point in patients with DKD.
Journal of the American Heart Association
FEBRUARY 16, 2024
BackgroundInhibition of prostaglandin synthesis by nonsteroidal anti‐inflammatory drugs is associated with cardiovascular mortality and kidney disease. Longitudinal associations with cardiovascular mortality and kidney outcomes (eGFR <60 or <45 mL/min per 1.73
Circulation
JANUARY 27, 2025
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
HCPLive
DECEMBER 30, 2024
Panelists discuss the new health measures relevant to chronic kidney disease (CKD) management and their significance in improving patient care and outcomes.
105 
Med Page Today
APRIL 15, 2024
(MedPage Today) -- A multi-pronged electronic health record-based population health management intervention failed to move the needle for slowing chronic kidney disease (CKD) progression, a cluster randomized trial showed. Over a median follow.
The New England Journal of Medicine
MARCH 28, 2025
Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.
75 
HCPLive
NOVEMBER 25, 2024
Panelists discuss how early detection of chronic kidney disease (CKD) in stages 2 and 3 can improve patient outcomes across various specialties, including nephrology, cardiology, and primary care.
The British Journal of Cardiology
MARCH 4, 2025
Acute coronary syndrome (ACS) events in people receiving long-term haemodialysis (HD) are common, present atypically and are associated with poor outcomes. 57 These are some of the reasons that the combination of cardiac and renal disease strike fear into even the most seasoned clinicians.
HCPLive
AUGUST 31, 2024
Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.
Journal of the American Heart Association
DECEMBER 24, 2024
BackgroundThis realworld evidence study compared risks of cardiovascular events in hospital settings among patients with chronic kidney disease (CKD) with and without hyperkalemia.Methods and ResultsAdults with CKD stages 3b/4 with and without hyperkalemia were identified from Optum's deidentified Market Clarity Data (January 2016August 2022).
HeartRhythm
SEPTEMBER 11, 2024
End-stage kidney disease (ESKD) patients are prone to bloodstream infections which may result in a higher risk of cardiac implantable electronic device (CIED) infections.
American College of Cardiology
MARCH 29, 2025
The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.
HCPLive
JUNE 6, 2024
Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.
Hypertension Journal
DECEMBER 5, 2024
BACKGROUND:Intensive blood pressure (BP) control in youth with chronic kidney disease (CKD) slows progression, delaying the need for kidney replacement therapy (KRT). Hypertension, Ahead of Print. Most youth with CKD have hypertension and BP control is difficult to achieve outside of controlled experimental settings.
HeartRhythm
NOVEMBER 28, 2024
Patients with chronic kidney disease (CKD) on renal replacement therapy (RRT) are at high risk for cardiovascular implantable electronic device (CIED) infections. Although device extraction is standard management, it is often avoided in these patients due to high procedural risks.
HeartRhythm
JULY 15, 2024
Limited data are available on leadless pacemaker (LPM) outcomes according to different stages of chronic kidney disease (CKD).
Med Page Today
MARCH 10, 2025
(MedPage Today) -- Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently published guideline -- serving.
Open Heart
OCTOBER 31, 2024
Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers. Our findings suggest that monitoring and managing SUA could be crucial in improving patient with HF outcomes.
Cardiovascular Diabetology
JULY 3, 2024
Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we.
64 
HCPLive
MAY 16, 2024
Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.
59 
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidney disease (ESKD) undergoing dialysis is limited.
Coronary Artery Disease Journal
JUNE 18, 2024
Background Advanced chronic kidney disease (ACKD) is common in patients undergoing percutaneous coronary intervention (PCI) and is associated with adverse outcomes. These patients are often excluded from revascularization studies. The goal of this study was to evaluate the impact of ACKD in patients undergoing PCI.
HeartRhythm
NOVEMBER 5, 2024
Chronic kidney disease (CKD) and kidney failure with replacement therapy (KFRT) are prevalent in patients with atrial fibrillation (AF).
DAIC
JANUARY 8, 2025
a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. The primary outcome measure is absolute change in the frequency of apnea-hypopnea episodes. tim.hodson Wed, 01/08/2025 - 14:11 Jan.
HCPLive
MARCH 25, 2024
Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
The American Journal of Cardiology
OCTOBER 23, 2024
Publication date: Available online 22 October 2024 Source: The American Journal of Cardiology Author(s): Nathan W. Kong, Joseph M. Kim, Anna K. Krawisz, Patrick Heindel, Archana Tale, Yang Song, Jeffrey L. Weinstein, Mohamad A. Hussain, Eric A.
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Hypertension Journal
SEPTEMBER 14, 2023
BACKGROUND:Hypertension frequently accompanies chronic kidney disease (CKD) as etiology and sequela. Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. We defined CKD as a sustained estimated glomerular filtration rate value <60 mL/min per 1.73 m2or a urine albumin-to-creatinine ratio ≥30 mg/g.
Journal of the American Heart Association
MARCH 13, 2025
Main outcome was SCA identified byInternational Classification of Diseases, Tenth Revision (ICD10).Participants The influence of proteinuria on SCA was stronger in advanced chronic kidney disease (stage 3 and stage 45).ConclusionsProteinuria Urine protein was measured using the spot urine dipstick method.
American College of Cardiology
DECEMBER 23, 2024
The goal of the EMPA-KIDNEY trial was to assess the safety and efficacy of empagliflozin in improving cardiac and renal outcomes among patients with chronic kidney disease (CKD).
MIBHS
DECEMBER 27, 2024
Anemia of chronic disease : A type of anemia commonly seen in patients with long-term health conditions such as kidney disease or heart disease. Identifying and addressing preoperative anemia before surgery is an important strategy for reducing risks and ensuring better outcomes after heart bypass surgery.
JAMA Cardiology
JANUARY 31, 2021
This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.
40 
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Cardiovascular Diabetology
AUGUST 6, 2024
Cox proportional survival analysis was used to assess outcomes where cardioprotective GLD (any of Sodium Glucose Lowering Transport 2 receptor inhibitors [SGLT2i] and Glucagon Like Peptide Receptor Agonists [GLP-1 RA]) served as a reference. vs. 10.5%) and chronic kidney disease (3.7% vs. 6.8%), myocardial infarction (7.7%
Clinical Trial Results
NOVEMBER 18, 2024
Tuttle_Bakris AHA 2024 FLOW kidney outcomes by BL CV_8Nov2024 Download Disclosures: TBD
40 
HCPLive
NOVEMBER 18, 2024
Panelists discuss the current barriers to urine albumin-creatinine ratio (uACR) testing, strategies to address these barriers, the guideline goals for reducing uACR, and the importance of a multimodal approach, as well as how increased awareness of chronic kidney disease (CKD) testing can improve patient outcomes and engage health care providers in (..)
The American Journal of Cardiology
DECEMBER 13, 2023
Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): David Song, Yasar Sattar, Mohammed Faisaluddin, Usama Talib, Neel Patel, Izza Shahid, Amro Taha, Fnu Raheela, Prasana Sengodon, Maria Riasat, Vaibhav Shah, Karthik Gonuguntla, Mahboob Alam, Islam Elgendy, Ramesh Daggubati, M. Chadi Alraies
40 Journal of the American Heart Association
MARCH 27, 2025
The primary outcome was a composite of inhospital adverse events. Associations between multimorbidity patterns and outcomes were evaluated using multivariableadjusted logistic regression models. years]) admitted to the China Chest Pain Center Database between 2016 and 2021. Among 9570 patients, 50% (n=4789) had multimorbidity.
Heart BMJ
OCTOBER 10, 2024
Indeed, numerous studies are currently investigating the impact of such approaches on clinical outcomes and healthcare utilisation. Accordingly, the management of AF has shifted towards a holistic and integrated approach, targeting comorbidities and risk factors, itself associated with improved outcomes. 2 Before the. 2 Before the.
Journal of Cardiovascular Pharmacology
SEPTEMBER 4, 2023
Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD. Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD.
Circulation
NOVEMBER 11, 2024
This study evaluates the outcomes in patients admitted for HF with and without hyperkalemia.Methods:We used the Nationwide Readmissions Database (NRD) from 2016-2019, extracting adult patients with a primary diagnosis of HF who were admitted between January and November of each year. vs. 2.5%, p < 0.001). 2], p<0.001).Conclusion:Hyperkalemia
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content